{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:34Z","timestamp":1790188294269,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAR"],"published-print":{"date-parts":[[2018,10,29]]},"abstract":"<jats:sec>\n<jats:title>Background: <\/jats:title>\n<jats:p>Bapineuzumab is a humanized anti-amyloid-beta (A\u03b2) monoclonal antibody\ndirected at lowering the cerebral A\u03b2 deposit in Alzheimer\u2019s disease (AD).\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>\nThis phase 2, open-label extension (OLE) study evaluated long-term safety and efficacy of\nbapineuzumab in patients with the mild-to-moderate AD.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> Patients (58-78 years) who completed either of two randomized, placebo-controlled, doubleblind\nstudies (subcutaneous [SC] single-dose-escalation, or intravenous (IV) multiple-ascending-dose))\nentered the OLE. Three groups were assessed: bapineuzumab or placebo SC, and bapineuzumab (IV) in\nOLE (bapi SC\/bapi IV); bapineuzumab (IV) in Study 201 and OLE (bapi\/bapi); and placebo in Study\n201 and bapineuzumab IV in OLE (placebo\/bapi).\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Of 194 patients enrolled, 158 withdrew from OLE; primarily due to withdrawal by subject\n(n=85) and AE (n=30). Mean (SD) bapineuzumab exposure was 2.9 (1.90) years. There were no significant\ndifferences for efficacy endpoints (AD Assessment Scale\u2013cognitive subscale [ADAS-Cog], Disability\nAssessment for Dementia [DAD] and MMSE scores) between the bapi\/bapi and placebo\/bapi\ngroups. Most patients (94.8%, 184\/194) reported \u22651 treatment-emergent adverse events (TEAEs) in\nOLE. Amyloid-related imaging abnormalities with effusion or edema (ARIA-E) occurred in 22 (11.3%)\npatients. The most common TEAEs (&gt;20% patients) were fall, agitation and urinary tract infection with\nsimilar incidences between bapi\/bapi and placebo\/bapi groups.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> No significant difference was seen in cognitive and functional decline between early and\ndelayed treatment groups. No new safety concerns emerged. ARIA-E incidence was higher in patients\nfirst exposed to bapineuzumab in OLE versus previously exposed. No clear pattern of etiology contributed\nto death events.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567205015666180821114813","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T11:58:31Z","timestamp":1534852711000},"page":"1231-1243","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer\u2019s Disease: A Phase 2, Open-Label Extension Study"],"prefix":"10.2174","volume":"15","author":[{"given":"Stephen","family":"Salloway","sequence":"first","affiliation":[{"name":"The Warren Alpert Medical School of Brown University, 345 Blackstone Boulevard, Providence, RI 02906, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad A.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Center for Alzheimer Research & Treatment, Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Springhouse, PA 19002, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Robert","family":"Brashear","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Pennington, NJ 08534, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Alzheimer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/164828","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/164828\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/164828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T16:01:53Z","timestamp":1609257713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/164828\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":0,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,10,29]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567205015666180821114813","relation":{},"ISSN":["1567-2050"],"issn-type":[{"value":"1567-2050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}